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Azithromycin for community treatment of suspected 
COVID-19 in people at increased risk of an adverse clinical 
course in the UK (PRINCIPLE): a randomised, controlled, 
open-label, adaptive platform trial
PRINCIPLE Trial Collaborative Group*
Summary
Background Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to 
treat COVID-19, but evidence from community randomised trials is lacking. We aimed to assess the effectiveness 
of azithromycin to treat suspected COVID-19 among people in the community who had an increased risk of 
complications.
Methods In this UK-based, primary care, open-label, multi-arm, adaptive platform randomised trial of interventions 
against COVID-19 in people at increased risk of an adverse clinical course (PRINCIPLE), we randomly assigned 
people aged 65 years and older, or 50 years and older with at least one comorbidity, who had been unwell for 14 days 
or less with suspected COVID-19, to usual care plus azithromycin 500 mg daily for three days, usual care plus other 
interventions, or usual care alone. The trial had two coprimary endpoints measured within 28 days from randomisation: 
time to first self-reported recovery, analysed using a Bayesian piecewise exponential, and hospital admission or death 
related to COVID-19, analysed using a Bayesian logistic regression model. Eligible participants with outcome data 
were included in the primary analysis, and those who received the allocated treatment were included in the safety 
analysis. The trial is registered with ISRCTN, ISRCTN86534580.
Findings The first participant was recruited to PRINCIPLE on April 2, 2020. The azithromycin group enrolled 
participants between May 22 and Nov 30, 2020, by which time 2265 participants had been randomly assigned, 540 to 
azithromycin plus usual care, 875 to usual care alone, and 850 to other interventions. 2120 (94%) of 2265 participants 
provided follow-up data and were included in the Bayesian primary analysis, 500 participants in the azithromycin 
plus usual care group, 823 in the usual care alone group, and 797 in other intervention groups. 402 (80%) of 
500 participants in the azithromycin plus usual care group and 631 (77%) of 823 participants in the usual care alone 
group reported feeling recovered within 28 days. We found little evidence of a meaningful benefit in the azithromycin 
plus usual care group in time to first reported recovery versus usual care alone (hazard ratio 1·08, 95% Bayesian 
credibility interval [BCI] 0·95 to 1·23), equating to an estimated benefit in median time to first recovery of 0·94 days 
(95% BCI –0·56 to 2·43). The probability that there was a clinically meaningful benefit of at least 1·5 days in time to 
recovery was 0·23. 16 (3%) of 500 participants in the azithromycin plus usual care group and 28 (3%) of 823 participants 
in the usual care alone group were hospitalised (absolute benefit in percentage 0·3%, 95% BCI –1·7 to 2·2). There 
were no deaths in either study group. Safety outcomes were similar in both groups. Two (1%) of 455 participants in 
the azothromycin plus usual care group and four (1%) of 668 participants in the usual care alone group reported 
admission to hospital during the trial, not related to COVID-19.
Interpretation Our findings do not justify the routine use of azithromycin for reducing time to recovery or risk of 
hospitalisation for people with suspected COVID-19 in the community. These findings have important antibiotic 
stewardship implications during this pandemic, as inappropriate use of antibiotics leads to increased antimicrobial 
resistance, and there is evidence that azithromycin use increased during the pandemic in the UK.
Funding UK Research and Innovation and UK Department of Health and Social Care.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
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Introduction
Identifying treatments that can be used to speed recovery 
and reduce hospitalisations due to COVID-19 in the 
community is critically important, particularly among 
older adults and people with comorbidities, who are at a 
high risk of adverse outcomes.1 Azithromycin, a licensed, 
widely available, cheap, and generally safe drug has 
been proposed as a treatment for COVID-19, with 
in-vitro studies suggesting activity against some viruses, 
including SARS-CoV-2.2,3 Azithromycin might increase 
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the pH of the Golgi network and recycling endosome,4 
which could in turn interfere with intracellular 
SARS-CoV-2 activity and replication. The drug might 
also reduce levels of the enzyme furin;4 this could 
interfere with the ability of SARS-CoV-2 to enter cells, as 
the virus is believed to have a furin-like cleavage site in 
the spike protein.5 The ability of azithromycin to reduce 
the levels of proinflammatory cytokines, such as IL-6,6 
could reduce the ability of SARS-CoV-2 infection to 
trigger a cytokine storm, along with associated tissue 
damage. Furthermore, some patients with viral 
respiratory illness might develop a secondary bacterial 
infection or present with a bacterial co-infection, which 
azithromycin could effectively treat. Azithromycin use 
in primary care has increased during the COVID-19 
pandemic,7 which could contribute to antimicrobial 
resistance.8
Randomised trials have found that azithromycin is 
not an effective treatment for patients who are admitted 
to hospital with COVID-19, either alone or in 
combination with hydroxychloroquine.9–11 However, 
there is a paucity of evidence regarding the effectiveness 
of azithromycin for treatment of suspected COVID-19 
in the community, where earlier treatment might 
speed recovery and prevent hospital admissions. We 
aimed to assess the effectiveness of azithromycin to 
treat COVID-19 in the platform randomised trial of 
interventions against COVID-19 in older people 
(PRINCIPLE) study.
Methods
Study design and participants
PRINCIPLE is the UK National Urgent Public Health 
Priority open-label, multi-group, prospective, adaptive 
platform, randomised clinical trial in com munity care. 
A platform trial is an adaptive clinical trial in which 
multiple treatments for the same disease can be tested 
simultaneously. Participants are randomly assigned to 
either usual care or an intervention, where an intervention 
consists of the intervention active agent plus usual care. A 
master protocol defines prospective decision criteria to 
allow for stopping an intervention for futility, declaring 
an intervention superior, or adding a new intervention 
to be evaluated.12 Interventions currently or previously 
evaluated in PRINCIPLE include hydroxychloroquine, 
azithromycin, doxycycline, and inhaled budesonide. 
Here, we report outcomes for azithromycin, which was 
the second intervention included in the trial.
People in the community were eligible if they were 
aged 65 years and older, or 50 years and older with 
comorbidities, and with ongoing symptoms from 
PCR-confirmed or suspected COVID-19 (in accordance 
with the UK National Health Service [NHS] syndromic 
case definition of high temperature, a new, continuous 
cough, or a change in sense of smell or taste).13,14 Symp-
toms must have started within the past 14 days. 
Comorbidities required for eligibility in those aged 
50–65 years were as follows: known weakened immune 
system due to a serious illness or medication (eg, 
Research in context
Evidence before this study
We searched PubMed on Jan 24, 2021, using the following 
search terms [(randomised OR trial) AND (azithromycin OR 
macrolide) AND (COVID* OR SARS-CoV-2 OR SARS-CoV)], 
with no language restrictions, and identified 243 results. 
Adding a filter for clinical trials limited the number of results 
to 16. Of these, we identified two randomised clinical trials with 
over 100 participants that provided some data on the 
effectiveness of azithromycin as a treatment for COVID-19 
compared with control treatment or usual care. Additional 
searches of medRxiv and Google Scholar on Jan 24, 2021, using 
similar search terms with no language restrictions, identified a 
further randomised clinical trial of azithromycin. All identified 
trials were in hospitalised patients. A large randomised trial 
among patients hospitalised with COVID-19 in the UK found no 
difference in 28-day mortality, duration of hospital stay or 
treatment in hospital, or intensive care unit admissions among 
2582 participants randomly assigned to receive azithromycin 
versus 5181 participants randomly assigned to receive usual 
care alone. A randomised trial in Brazil among 675 patients 
admitted to hospital with mild to moderate COVID-19 found 
no difference in clinical status by 15 days among patients 
randomly assigned to receive usual care plus azithromycin and 
hydroxychloroquine versus usual care plus hydroxychloroquine, 
versus usual care alone. A trial by the same group, among 
447 patients admitted to hospital with severe COVID-19, 
found that patients randomly assigned to azithromycin plus 
hydroxychloroquine, versus hydroxychloroquine alone, 
had poorer clinical status at 15 days, although outcomes were 
more similar between the two groups by 29 days. We identified 
no randomised clinical trials of azithromycin as a treatment for 
COVID-19 in the community.
Added value of this study
All three randomised clinical trials that we identified were in 
hospital settings, and only one assessed azithromycin as a 
standalone therapy for COVID-19. To our knowledge, PRINCIPLE 
is the first randomised trial to assess the effectiveness and 
safety of azithromycin as a standalone treatment for patients 
with COVID-19 in the community. We found that azithromycin 
did not substantially improve time to recovery and found little 
evidence of an effect on admissions to hospital, when used in 
the community to treat COVID-19.
Implications of all the available evidence
Taken together, our findings plus the evidence to date 
suggest that azithromycin is not a sufficiently effective 
treatment to justify routine use for treatment of COVID-19, 
neither in the community nor in hospitals.
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chemotherapy); known heart disease or a diagnosis of 
high blood pressure; known asthma or lung disease; 
known diabetes; known mild hepatic impairment; or 
known stroke or neurological problems. People were 
ineligible to be randomly assigned between azithromycin 
and usual care if they were already receiving acute 
antibiotics, or had a contraindication to azithromycin as 
identified in the summary of product characteristics and 
British National Formulary.
Initially, eligible individuals were recruited, screened, 
and enrolled through participating general practices. 
From May 17, 2020, people across the UK were able to 
enrol online or by telephone with study team support. 
After patients completed a baseline and screening ques-
tionnaire, a clinician or trained research nurse confirmed 
eligibility using the patient’s primary care medical record, 
accessed remotely where necessary, before randomisation. 
Given the increased risk from COVID-19 among Black, 
Asian, and minority ethnic communities,15 we actively 
reached out to a range of religious and community 
organisations at national and regional levels to increase 
participation from diverse backgrounds.
The trial was approved by the UK Medicines and 
Healthcare products Regulatory Agency (MHRA) and the 
South Central—Berkshire Research Ethics Committee 
under the authority of the United Kingdom Ethics 
Com mittee Authority under the Medicines for Human 
Use (Clinical Trials) Regulations 2004 (ethics reference 
20/SC/0158). Online informed consent was obtained from 
all participants, with the opportunity to discuss queries 
with the trial team by telephone. The trial is coordinated 
by the Oxford Primary Care Clinical Trials Unit, 
Nuffield Department of Primary Care Health Sciences at 
the University of Oxford (Oxford, UK), and conducted 
in accordance with the principles of the Declaration 
of Helsinki and the International Conference on 
Harmonization—Good Clinical Practice guidelines. The 
protocol, and details of how to participate, are available 
online.
Randomisation and masking
Participants were randomly assigned using an in-house, 
secure, fully validated and compliant web-based ran-
domisation sys tem called Sortition (version 2.3). Initially, 
randomisation was fixed at 1:1 allocation between usual 
care plus azithromycin and usual care alone, with 
stratification by age (<65 years vs ≥65 years) and presence 
of comorbidities (yes vs no). After doxycycline was 
added to the trial on July 24, 2020, subsequent 
randomisation ratios were determined via response 
adaptive randomisation through regularly scheduled 
interim analyses. Details for implementing response 
adaptive randomisation were prespecified in the adaptive 
design report; the general idea is to allocate more 
participants to the intervention groups that have the best 
observed time to first recovery outcomes (appendix p 77). 
The trial team was masked to the randomisation ratios.
Procedures
The intervention presented in this manuscript is oral 
azithromycin 500 mg once daily for three days plus usual 
care, compared with usual care alone. Usual care in 
the NHS for suspected COVID-19 in the community is 
largely supportive and focused on managing symptoms.16 
Antibiotics are only recommended for use if bacterial 
pneumonia is suspected, in which case guidelines 
recommend doxycycline.17 Azithromycin was either 
prescribed or issued directly by the participant’s general 
practitioner (GP), or issued centrally by the trial team 
and delivered to the participant. Azithromycin 500 mg is 
commonly used in primary care for bacterial respiratory 
infections and is similar to the dose used in early studies 
for COVID-19.18
The PRINCIPLE trial initially had two groups, with 
1:1 allo cation between usual care and hydroxy chloroquine. 
The first participant was recruited on April 2, 2020, and 
the hydroxychloroquine group of the trial was closed 
by the UK MHRA on May 22, 2020, at which point 
azithromycin was introduced. Participants were followed 
up by responding to questions about their symptoms, 
antibiotic use, and use of health-care services in a daily, 
online diary for 28 days after random assignment, 
supplemented with telephone calls on days 2, 14, and 28. 
Participants were encouraged to nominate a friend, 
relative, or carer to be a study partner, who could help 
them provide follow-up data, and be contacted for 
information if the participant was unable to complete the 
daily diary themselves. We obtained consent to ascertain 
relevant outcome data from GP and hospital records 
about hospital assessments, admissions, inten sive care 
treatment, and mechanical ventilation. We aimed to give 
all participants the opportunity to provide a self-swab test 
for SARS-CoV-2 infection, analysed by the Public Health 
England virology reference laboratory but, because of 
supply issues during the early stages of the pandemic, 
swabs were not available for all participants.
Outcomes
The trial commenced with a single primary outcome: 
hospitalisation or death within 28 days. However, the 
proportions of people in the community requiring 
hospitalisation were much lower in the UK than seen in 
initial data from China, meaning a different outcome 
would be required to allow rapid evaluation of various 
interventions within reasonable sample sizes.19 The 
trial management and steering committees therefore 
recommended that the primary outcome be amended to 
include a measure of illness duration.20,21 This change was 
approved by the research ethics committee and the 
MHRA on September 16, 2020, and implemented before 
any interim analyses were done. Thus, the trial has 
coprimary endpoints, as follows: time to first self-reported 
recovery within 28 days from random assignment, with 
time to recovery defined as the first instance that a 
participant reported feeling recovered (ascertained by 
For more on the British National 
Formulary see https://bnf.nice.
org.uk/
For the protocol and further 
information on the PRINCIPLE 
trial see www.principletrial.org
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answering the question, “Do you feel recovered today? ie, 
symptoms associated with illness are no longer a 
problem. Yes/No”); and hospital admission or death 
within 28 days of random assignment. Data for the time 
to recovery outcome were collected from the daily diary 
filled in by participants. Hospital admission and death 
data were collected from the daily diary, medical notes 
obtained either directly from GPs or via the Oxford Royal 
College of General Practice Research and Surveillance 
Centre,22 and also the Secondary Uses Service provided by 
the UK NHS Digital.23 These data were centrally processed 
by the trial data management team.
Secondary outcomes were a rating of how well 
participants felt (“How well are you feeling today? Please 
rate how you are feeling now using a scale of 1–10, where 
1 is the worst you can imagine, and 10 is the best you can 
imagine”); time to sustained recovery (date participant 
first reported feeling recovered and subsequently 
remained well until 28 days after random assignment); 
time to initial alleviation of symptoms; time to sustained 
alleviation of symptoms (date participant first reported all 
symptoms as minor or none, with no subsequent increase 
in symptoms until 28 days after random assignment); 
time to initial reduction of severity of symptoms; 
contacts with health services; hospital assessment without 
admission; oxygen administration; intensive care unit 
admission; mechanical ventilation (components of the 
WHO ordinal scale); prescription of antibiotics other than 
850 allocated to other treatment arms
 
53 excluded
 2 recovered at day 0
 24 no diary information
 27 other reasons 
875 allocated to usual care alone
862 received usual care
13 excluded
 3 ineligible
 10 withdrew consent and no 
medical notes review*





8 withdrew consent and no medical 
notes review*
797 included in primary analysis population
311 included in SARS-CoV-2-positive 
analysis population for primary analysis 
607 included in concurrent randomisation 
analysis population
823 included in primary analysis population 
236 included in SARS-CoV-2-positive 
analysis population for primary analysis
629 included in concurrent randomisation 
analysis population
 
29 464 patients screened for eligibility
 
3289 registered for GP eligibility check
2265 randomised
39 excluded
6 recovered at day 0
33 no diary information* 
 
500 included in primary analysis population
186 included in SARS-CoV-2-positive 
analysis population for primary analysis
500 included in concurrent randomisation 
analysis population
26 175 not eligible
1024 excluded
 672 ineligible
 28 unable to contact patient 
 72 no response from patient
 40 no response from GP 
 39 no consent or baseline from patient
 13 participant no longer wished to take part
 7 patient not registered with the GP
 4 GP refused
 29 awaiting participant response
 120 eligibility check in process
26 excluded
 1 recovered at day 0
 25 no diary information*
Figure 1: Trial profile
GP=general practitioner. *Participants provided no diary information.
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the trial antibiotics; effects in those with a positive 
test for SARS-CoV-2 infection; and the WHO-5 Well-
Being Index.24 The WHO-5 Well-Being Index includes 
five items relating to wellbeing measured on a five-point 
scale (appendix p 210). A total score is computed by 
summing the scores to the five individual questions to 
give a raw score ranging from 0 to 25, which is then 
multiplied by 4 to give the final score, with 0 representing 
the worst imaginable wellbeing and 100 representing the 
best imaginable wellbeing. We measured sustained 
recovery and sustained alleviation of symptoms because 
of the recurrent nature of COVID-19 illness.
Serious adverse events other than hospitalisation or 
death due to COVID-19 were assessed by the clinical 
team for relatedness to and whether they were expected 
with the trial treatment.
Statistical analysis
For the primary outcome analyses, assuming a median 
time to first recovery of 9 days in the usual care alone 
group, around 400 participants per group (800 partici pants 
in total if only a single intervention vs usual care alone) 
would be required to provide 90% power for detecting a 
difference of 2 days in median time to first recovery 
(approximate hazard ratio [HR] 1·3). Additionally, around 
1500 participants per group (3000 participants in total 
if only a single intervention vs usual care alone) would 
be required to provide 90% power for detecting a 
50% reduction in the relative risk of hospitalisation or 
death, assuming a hospitalisation rate of 5% in the 
control group and 2·5% in the intervention group. These 
calculations are approximations that do not explicitly 
account for adaptations of the platform design. In the 
adaptive design report (appendix pp 68–80), we provide a 
more complete justification of sample size by simulating 
the operating characteristics of the adaptive design in 
multiple scenarios, which explicitly account for response 
adaptive randomisation, early stopping for futility or 
success, and multiple interventions.
The primary analysis population is defined as all 
eligible randomly assigned participants for whom data 
were available, with participants analysed according to 
the groups they were randomly allocated to, regardless of 
deviation from the protocol and irrespective of their 
COVID-19 status.
The first coprimary outcome, time to first recovery, was 
analysed using a Bayesian piecewise exponential model 
regressed on treatment and stratification covariates (age 
and comorbidity), and included parameters for time 
interval (0–7 days, 8–14 days, 15–21 days, and >21 days 
from random allocation). The second coprimary outcome, 
hospitalisation or death, was analysed using a Bayesian 
logistic regression model regressed on treatment and 
stratification covariates (age and comorbidity). We 
included these stratifi cation covariates in the primary 
analysis as response adaptive randomisation increases the 
risk of imbalance on these variables. The coprimary 
Azithromycin plus 
usual care (n=526)




Age (years) 60·9 (7·9) 60·5 (7·8) 60·7 (7·8)
Age by 5-year bands (years)
50–54 131 (25%) 236 (27%) 367 (26%)
55–59 130 (25%) 219 (25%) 349 (25%)
60–64 84 (16%) 123 (14%) 207 (15%)
65–69 108 (21%) 153 (18%) 261 (19%)
70–74 48 (9%) 90 (10%) 138 (10%)
75–79 13 (2%) 30 (3%) 43 (3%)
80–84 7 (1%) 8 (1%) 15 (1%)
85–89 4 (1%) 2 (<1%) 6 (<1%)
90–94 1 (<1%) 1 (<1%) 2 (<1%)
Sex
Female 301 (57%) 486 (56%) 787 (57%)
Male 224 (43%) 375 (44%) 599 (43%)
Missing data 1 (<1%) 1 (<1%) 2 (<1%)
Comorbidity
No 63 (12%) 102 (12%) 165 (12%)
Yes 463 (88%) 760 (88%) 1223 (88%)
Ethnicity†
White 434 (83%) 700 (82%) 1134 (82%)
Mixed background 10 (2%) 22 (3%) 32 (2%)
South Asian 21 (4%) 34 (4%) 55 (4%)
Black 2 (<1%) 5 (1%) 7 (1%)
Other 12 (2%) 9 (1%) 21 (2%)
Missing data 47 (9%) 92 (11%) 139 (10%)
Duration of illness before randomisation 
(days)
6 (4–9) [0–28] 6 (4–10) [0–63]‡ 6 (4–10) [0–63]
Smoking status
Current smoker 62 (12%) 117 (14%) 179 (13%)
Former smoker 187 (36%) 317 (37%) 504 (36%)
Never smoker 264 (50%) 403 (47%) 667 (48%)
Missing data 13 (2%) 25 (3%) 38 (3%)
Swab result within 28 days of randomisation
Negative 266 (51%) 439 (51%) 705 (51%)
Positive 189 (36%) 245 (28%) 434 (31%)
No result 2 (<1%) 7 (1%) 9 (1%)
Missing data 69 (13%) 171 (20%) 240 (17%)
Asthma, chronic obstructive pulmonary 
disease, or lung disease
193 (37%) 329 (38%) 522 (38%)
Diabetes 90 (17%) 162 (19%) 252 (18%)
Heart problem§ 86 (16%) 126 (15%) 212 (15%)
High blood pressure for which medication 
is being taken
209 (40%) 368 (43%) 577 (42%)
Liver disease 16 (3%) 23 (3%) 39 (3%)
Stroke or other neurological problem 31 (6%) 52 (6%) 83 (6%)
Taking angiotensin-converting enzyme 
inhibitor¶
103 (20%) 179 (21%) 282 (20%)
Missing data 2 (<1%) 4 (<1%) 6 (<1%)
Fever at baseline
No problem 222 (42%) 372 (43%) 594 (43%)
Minor problem 164 (31%) 300 (35%) 464 (33%)
Moderate problem 122 (23%) 168 (19%) 290 (21%)
Major problem 18 (3%) 22 (3%) 40 (3%)
(Table 1 continues on next page)
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outcomes were evaluated using a so-called gate-keeping 
strategy. For a given treatment, the hypothesis for the time 
to first recovery endpoint was evaluated first and, if the 
recovery null hypothesis was rejected, the hypothesis for 
the second coprimary endpoint of hospitalisation or death 
was evaluated. This gate-keeping strategy preserves the 
overall type I error of the primary endpoints without 
additional adjustments for multiple hypotheses. In the 
context of multiple interim analyses, the master protocol 
specified each null hypothesis to be rejected if the 
Bayesian posterior probability of superiority exceeded 
0·99 for the time to recovery endpoint and 0·975 
(via gate-keeping) for the hospitalisation or death 
endpoint. Based on trials of antibiotics for lower 
respiratory tract infection,25 a minimum of 1·5 days 
difference in median time to first self-reported recovery 
and 2% point difference in hospitalisation or mortality 
were considered to be clinically meaningful and were 
prespecified in the adaptive design report.
Per the prespecified protocol, the primary analysis 
model included all participants randomly allocated to 
azithromycin plus usual care, usual care alone, and other 
trial interventions, from the start of random assignment 
in the platform to the time of the last random allocation 
to azithromycin (Nov 30, 2020). Data were extracted from 
the database after all randomly allocated participants had 
the opportunity to complete 28 days follow-up. Because 
this population included participants randomly assigned 
to usual care alone before the azithromycin group was 
opened, the time to recovery model also includes 
parameters to adjust for temporal drift in the study 
population. This adjustment can capture temporal drift 
due to changes in SARS-CoV-2, usual care, or the 
pandemic situation, as well as changes in the inclusion or 
exclusion criteria over time, when including participants 
receiving non-concurrent usual care in the analyses.
We did sensitivity analyses of the primary outcomes on 
the concurrent randomisation analysis population, 
defined as all participants who were randomly assigned to 
azithromycin plus usual care, usual care alone, or other 
interventions only during the time interval when 
azithromycin was open to random allocation. Analyses 
of the coprimary outcomes for the concurrent ran-
domisation analysis population were done using the 
same methods as described for the primary analysis 
population. Analysis of the secondary outcomes was done 
in the concurrent randomisation analysis popula tion, but 
restricted to those in the azithromycin plus usual care 
and usual care alone groups only. Secondary time-to-
event outcomes were analysed using Cox proportional 
hazard models, and binary outcomes were analysed using 
logistic regression, adjusting for comor bidity status, age, 
duration of illness, and eligibility for azithromycin at 
baseline. We did not adjust for baseline covariates for 
outcomes with low event rates. We did prespecified 
subgroup analyses of time to recovery for baseline severity 
score and duration of illness before random assignment, 
Azithromycin plus 
usual care (n=526)




(Continued from previous page)
Cough at baseline
No problem 94 (18%) 155 (18%) 249 (18%)
Minor problem 217 (41%) 335 (39%) 552 (40%)
Moderate problem 175 (33%) 317 (37%) 492 (35%)
Major problem 40 (8%) 55 (6%) 95 (7%)
Shortness of breath at baseline
No problem 205 (39%) 271 (31%) 476 (34%)
Minor problem 212 (40%) 380 (44%) 592 (43%)
Moderate problem 92 (17%) 192 (22%) 284 (20%)
Major problem 17 (3%) 19 (2%) 36 (3%)
Muscle ache at baseline
No problem 164 (31%) 266 (31%) 430 (31%)
Minor problem 193 (37%) 335 (39%) 528 (38%)
Moderate problem 134 (25%) 194 (23%) 328 (24%)
Major problem 35 (7%) 67 (8%) 102 (7%)
Nausea at baseline
No problem 392 (75%) 646 (75%) 1038 (75%)
Minor problem 96 (18%) 182 (21%) 278 (20%)
Moderate problem 32 (6%) 27 (3%) 59 (4%)
Major problem 6 (1%) 7 (1%) 13 (1%)
Feeling generally unwell (malaise) at baseline
No problem 31 (6%) 44 (5%) 75 (5%)
Minor problem 211 (40%) 291 (34%) 502 (36%)
Moderate problem 206 (39%) 263 (31%) 469 (34%)
Major problem 53 (10%) 38 (4%) 91 (7%)
Missing data 25 (5%) 226 (26%) 251 (18%)
Diarrhoea at baseline
No problem 356 (68%) 477 (55%) 833 (60%)
Minor problem 94 (18%) 110 (13%) 204 (15%)
Moderate problem 38 (7%) 39 (5%) 77 (6%)
Major problem 13 (2%) 10 (1%) 23 (2%)
Missing data 25 (5%) 226 (26%) 251 (18%)
Taken antibiotics since illness started 15 (3%) 37 (4%) 52 (4%)
Missing data 1 (<1%) 1 (<1%) 2 (<1%)
Use of health-care services
General practitioner 150 (29%) 243 (28%) 393 (28%)
Other primary care services 26 (5%) 53 (6%) 79 (6%)
UK National Health Service 111 86 (16%) 160 (19%) 246 (18%)
Accident and emergency department 6 (1%) 14 (2%) 20 (1%)
Other health-care services 47 (9%) 78 (9%) 125 (9%)
WHO-5 Well-Being Index score 49·9 (25·4) 49·5 (24·2) 49·7 (24·7)
Missing data 0 24 (3%) 24 (2%)
Data are mean (SD), n (%), or median (IQR) [range]. Severity of symptoms at baseline was self-reported. *Includes 
participants randomly assigned to usual care alone before the azithromycin group opened. †Data on ethnicity were 
collected retrospectively via medical notes review. ‡One participant had a duration of illness of 63 days at baseline due 
to a long pause between screening and consent by the participant; this participant subsequently withdrew from the 
study and did not contribute any diaries or notes review and so was not included in the primary analysis. §eg, angina, 
heart attack, heart failure, atrial fibrillation, or valve problems. ¶Such as ramipril, lisinopril, perindopril, captopril, 
or enalapril.
Table 1: Baseline characteristics of all eligible, randomly assigned participants by study group
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age, comorbidity, and SARS-CoV-2, using the concurrent 
randomisation analysis population to assess whether 
treatment effects varied across subgroups.
We also did secondary analyses restricted to participants 
who were positive for SARS-CoV-2, for the primary 
outcomes among the primary analysis population, and for 
the secondary outcomes in the concurrent randomisation 
analysis population. We compared serious adverse events 
in the as treated population (ie, the treatment that the 
participants received).
The master statistical analysis plan with full 
descriptions of definitions and analyses of outcomes was 
reviewed and signed off before the unblinding of results 
(appendix pp 168–207). An addendum to the plan was 
later added for further clarification of the analyses 
(pp 208–209). The adaptive design report details the 
analysis of the coprimary outcomes, including pre-
specified decisions at the interim analysis (appendix 
p 68). Because of concerns over trial integrity and 
confidentiality, we only present results corresponding 
to the primary analysis result and corresponding 
secondary outcomes and sensitivity for azithromycin, as 
randomisation and follow-up have been completed. 
Results from other trial groups will be presented in 
separate manuscripts when randomisation and follow-
up is complete for each group. We did not explore the 
potential impact of missing data because of the high 
proportion of participants contributing to the analysis of 
primary outcomes (94%).
Analyses were done using R (version 3.6.0) and Stata 
(version 16.1). The trial is registered with ISRCTN, 
ISRCTN86534580.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
On Nov 30, 2020, after review of planned interim 
analyses by the Data Monitoring and Safety Committee, 
the PRINCIPLE Trial Steering Committee advised the 
Trial Management Group to stop random assignment 
of patients to the azithromycin group of the trial because 
the prespecified futility criterion was met. By this date, 
2265 participants from 1460 GP practices were enrolled 
into PRINCIPLE across the UK (appendix p 210). 
679 (30%) of 2265 participants were enrolled directly 
through 231 GP practices and 1586 (70%) partici pants 
via online or telephone contact with the study team. 
540 participants were randomly allocated to azithro-
mycin plus usual care, 875 to usual care alone, and 
850 to other interventions. After exclusion of those who 
were ineligible, those who withdrew consent, and 
those without medical notes review and with no diary 
information available, 526 eligible participants were 
randomly assigned to receive azithromycin plus usual 
care, 862 to usual care alone, and 823 to other 
interventions (figure 1). 2120 (94%) of 2265 participants 
provided follow-up data and were included in the 
Bayesian primary analysis, 500 participants in the 
azithromycin plus usual care group, 823 in the usual 
care alone group, and 797 in other intervention groups. 
The concurrent randomisation analysis population 
included data from all partici pants randomly assigned 
to azithromycin plus usual care (n=500), and those 
concurrently assigned to usual care alone (n=629) for 
analysis of secondary outcomes, plus participants 
assigned to other interventions (n=607) for sensitivity 
analyses of coprimary outcomes (figure 1).
Characteristics of participants randomly assigned to 
azithromycin and concurrent controls were similar 
(table 1). The mean participant age was 60·7 years 
(SD 7·8), 1233 (88%) of 1388 participants had co morbid-
ities, and the median duration of illness before 
Azithromycin plus usual 
care
Usual care alone Estimated treatment effect 





Primary outcomes (primary analysis population)
First reported recovery 402/500 (80%) 631/823 (77%) ·· ·· ··
Time to first reported recovery 
(days)
7 (3 to 17) 8 (2 to 23) 1·08 (0·95 to 1·23)* 0·23* 0·89*
Hospitalisation or death at 
28 days
16/500 (3%) 28/823 (3%) 0·3% (–1·7 to 2·2)† 0·042† 0·64†
Primary outcomes (SARS-CoV-2-positive analysis population)
First reported recovery 136/186 (73%) 163/236 (69%) ·· ·· ··
Time to first reported recovery 
(days)
9 (4 to not reached) 13 (5 to not 
reached)
1·12 (0·91–1·38)* 0·47* 0·86*
Hospitalisation or death at 
28 days
11/186 (6%) 17/236 (7%) 1·6% (–3·1 to 6·2)† 0·43† 0·76†
Data are n/N (%) or median (IQR). HR=hazard ratio. *Estimated HR derived from a Bayesian piecewise exponential model adjusted for age and comorbidity at baseline, 
with 95% Bayesian credible interval. HR >1 favours azithromycin. †Estimated absolute benefit in percentage of hospitalisation or death derived from a Bayesian logistic 
regression model adjusted for age and comorbidity at baseline, with 95% Bayesian credible interval. A positive value favours azithromycin.
Table 2: Primary outcomes
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randomisation was 6 days (IQR 4–10). 1148 (83%) of 
1388 participants had a SARS-CoV-2 PCR result avail-
able, and 434 (31%) of 1388 participants had a positive 
result. 455 (87%) of 526 participants allocated to 
azithromycin plus usual care reported taking at least 
one dose of azithromycin and 374 (71%) took all 
three doses.
402 (80%) of 500 participants in the azithromycin plus 
usual care group and 631 (77%) of 823 participants in 
the usual care alone group reported feeling recovered 
within 28 days (table 2). Median time to first reported 
recovery for patients in the azithromycin plus usual care 
group was 7 days (IQR 3 to 17) and for patients in the 
usual care group was 8 days (2 to 23; figure 2; table 2). 
Based on the Bayesian primary analysis model, we 
found no evidence of a meaningful benefit in the 
azithromycin plus usual care group in time to first 
reported recovery versus usual care alone (HR 1·08, 
95% Bayesian credibility interval [BCI] 0·95 to 1·23), 
equating to an estimated benefit in median time to 
first recovery of 0·94 days (95% BCI –0·56 to 2·43; 
figure 2). The probability that median time to recovery 
was shorter in the azithromycin plus usual care 
group compared with the usual care alone group (ie, 
probability of superiority) was 0·89 and did not meet 
the 0·99 threshold to declare superiority. The probability 
that there was a clinically meaningful benefit of at least 
1·5 days in time to recovery was 0·23.
16 (3%) of 500 participants in the azithromycin plus 
usual care group and 28 (3%) of 823 participants in the 
usual care alone group were hospitalised (absolute benefit 
in percentage 0·3%, 95% BCI –1·7 to 2·2; table 2). There 
were no deaths in either study group. The probability that 
hospitalisations or deaths were lower in the azithromycin 
plus usual care group compared with the usual care alone 
group (probability of superiority) was 0·64, and was not 
formally analysed for significance due to the gate-keeping 
hypothesis structure. The probability that there was a 
reduction in hospitalisations or deaths of at least 2% (the 
predefined threshold of a clinically meaningful benefit) 
was 0·042. Results of both primary outcomes were 
consistent in participants with SARS-CoV-2 and the 
concurrent randomisation analysis population (table 2; 
figure 3).
Analysis of the secondary outcomes using the 
concurrent randomisation analysis population showed 
that there was no evidence of any difference between the 
two study groups in the daily score (1–10) of how well 
participants felt over 28 days (appendix p 217), nor the 
WHO wellbeing score at any of the follow-up timepoints, 
nor any of the hospitalisation secondary outcomes 
(table 3). Similarly, we found no evidence of treatment 
benefit in the azithromycin plus usual care group in time 
to first alleviation of symptoms, time to sustained 
alleviation of symptoms, and time to initial reduction of 
severity of symptoms (appendix p 218). More GP health-
care service use was reported in the azithromycin plus 
usual care group compared with the usual care alone 
group (table 3). We found some evidence that sustained 
recovery from nausea and vomiting and diarrhoea was 
more rapid in the azithromycin plus usual care group 
compared with the usual care alone group (appendix 
p 218).
In subgroup analyses, we found no impact of the 
duration of illness before random assignment nor of 
the baseline illness severity score on the time to first 
feeling recovered (figure 3). Estimates of treatment 
benefit were similar for those younger than 65 years and 
aged 65 years and older, as well as between those with 
and without comorbidities (figure 3). In patients who 
tested SARS-CoV-2 positive and received azithromycin, 
Figure 2: Summary and results of the time to first self-reported recovery
(A) Primary analysis population. (B) SARS-CoV-2-positive analysis population. Pr(meaningful effect) is the 
Bayesian model-based estimated probability that the benefit in median time to recovery compared with usual care 
is at least 1·5 days. Pr(superiority) is the probability of superiority; treatment superiority is declared if 
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we observed an estimated median benefit of 1·4 days 
(HR 1·12, 95% BCI 0·91–1·38; table 2) and a probability 
of benefit of 0·86, which was below the threshold for 
superiority of 0·99. Additional sensitivity analyses of 
interactions of swab results with time to first reported 
recovery in the concurrent randomisation analysis 
population supported these findings (appendix p 219). 
Results for the concurrent randomisation analysis 
population in SARS-CoV-2-positive participants for the 
secondary outcomes were similar to the concurrent 
randomisation analysis population results for all 
participants (appendix p 215).
One participant had side-effects from azithromycin 
and subsequently withdrew from the study. Two (1%) of 
455 participants in the azithromycin plus usual care 
group and four (1%) of 668 participants in the usual care 
alone group reported admission to hospital, unrelated to 
COVID-19, during the trial (p>0·99).
Discussion
In this trial of interventions for people with suspected 
COVID-19 within 14 days of symptom onset, and at 
increased risk of complications, azithromycin plus usual 
care did not substantially shorten the time to first self-
reported recovery or decrease the risk of hospitalisation.
There are over 80 clinical trials of azithromycin for 
COVID-19 planned or underway,3 but few have reported 
results and none, to our knowledge, are in a community 
setting. Similar to our findings, several randomised 
trials among patients admitted to hospital have found 
that azithromycin was not effective as a treatment for 
COVID-19. Azithromycin has been evaluated as part of a 
hospital-based, platform, open-label randomised clinical 
trial of different COVID-19 treatments in the UK.9 
2582 patients were randomly assigned to azithromycin 
(500 mg once a day for 10 days, or until discharge if this 
occurred sooner) plus usual care and 5181 received usual 
care alone. Azithromycin did not improve the primary 
outcome of mortality at 28 days (22% in both groups; 
rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). Similarly, 
the authors reported no difference in 28-day mortality 
between groups when the analyses were limited to 
patients with con firmed SARS-CoV-2 infection (rate 
ratio 0·95, 95% CI 0·86–1·06; p=0·38). There was no 
difference in the occurrence of new cardiac arrhythmias 
between groups. One serious adverse event attributed to 
azithromycin was reported (pseudomembranous colitis).
A Brazilian randomised clinical trial of hospitalised 
adults with known or suspected mild to moderate 
COVID-19 randomly assigned 667 patients to usual care 
alone (n=227), usual care plus hydroxychloroquine 
(n=221), or usual care plus hydroxychloroquine and 
azithromycin (500 mg once a day for 7 days; n=227).10 The 
primary outcome was clinical status at day 15, recorded 
on a 7-point ordinal scale from 1 (no longer in hospital 
and no limitation of activities) through to 7 (deceased). 
Among patients with confirmed COVID-19, the authors 
found that there was no difference in the odds of having 
poorer clinical status at day 15 between the groups 
(hydroxychloroquine plus azithromycin vs control odds 
ratio [OR] 0·99, 95% CI 0·57–1·73; p>0·99; hydroxy-
chloroquine plus azithromycin vs hydroxychloroquine 
OR 0·82, 95% CI 0·47–1·43; p>0·99). More participants 
who received hydroxychloroquine plus azithromycin and 
hydroxychloroquine alone had adverse events compared 
with the usual care alone group (39·3%, 33·7%, and 
22·6%, respectively). Prolongation of the corrected QT 
interval was most common in the hydroxychloroquine 
plus azithromycin group; however, the authors noted 
that participants in the usual care alone group were less 
likely to have electrocardiogram monitoring.
The same Brazilian study group conducted a trial of 
azithromycin 500 mg once daily for 10 days plus usual 
care versus usual care alone in 447 adult, hospitalised 
patients with severe COVID-19 (COALITION II).11 At the 
time of the trial, usual care for patients with severe 
COVID-19 was hydroxychloroquine 400 mg twice daily 
for 10 days. Thus, patients in the azithromycin group 
additionally received hydroxychloroquine. The authors 
reported no difference between the groups in the primary 
outcome of the odds of poorer clinical status at day 15, 
according to a 6-point ordinal scale of clinical status, 
among patients with confirmed COVID-19 (OR 1·36, 
95% CI 0·94–1·97; p=0·11). The proportion of serious 
adverse events between the intervention and control 
groups were similar (42% vs 38%; p=0·35), and there was 
no difference in patients with a prolonged corrected QT 
interval between the intervention and control groups 
(20% vs 21%; p=0·66). These studies provide good 
evidence that azithromycin is not an effective treatment 
in hospitalised COVID-19 patients. Furthermore, there 
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is no evidence of synergy between azithromycin and 
hydroxychloroquine in the context of COVID-19, as has 
previously been suggested.18,26,27
These data, in conjunction with our findings, suggest 
that despite potential antiviral and anti-inflammatory 
properties, azithromycin is not effective in treating 
COVID-19 without additional indications, even when 
used in the community and earlier in the course of the 
disease. A meta-analysis of 24 hospital-based studies 
found that bacterial co-infection (estimated from re spira-
tory or blood isolates on presentation with COVID-19) 
was identified in 3·5% of patients (95% CI 0·4–6·7),28 
suggesting that bacterial co-infection in the community 
is not common and, therefore, a beneficial effect through 
an antibacterial mechanism of action is unlikely in this 
setting.
Strengths of the PRINCIPLE trial include the 
evaluation of azithromycin as a standalone treatment in 
the community, with a focus on patients at a high risk of 
complications, and the use of 28-day patient-reported 
outcomes, which, in the case of hospitalisation and 
deaths, were confirmed by medical record review. Only 
around three-quarters of participants reported feeling 
recovered within 28 days, reflecting emerging evidence 
concerning the long-term nature of COVID-19 symp-
toms.29,30 Furthermore, recovery is not always sustained 
and COVID-19 symptoms can recur or relapse,30 which 
we measured using the secondary outcomes of sustained 
recovery and symptom alleviation. We did not assess the 
potential effects of azithromycin on long-term outcomes 
beyond 28 days.
We included patients with no SARS-CoV-2 PCR results 
because this reflects many primary care settings, where 
timely testing might not be available. At the beginning of 
the trial, shortages of swabs and restricted community 
testing resulted in a high proportion of participants with 
no timely SARS-CoV-2 test result available. We do not 
know how many participants who did not have a test, or 
who tested negative with a self-swab, might have tested 
positive if the swab had been taken by a health-care 
professional or earlier in their illness. Increased test 
availability has meant that the prevalence of known 
SARS-CoV-2 infection in participants enrolling into 
PRINCIPLE is now much higher. However, in the 
present analysis, only 434 (31%) of 1388 participants with 
suspected COVID-19 had PCR-confirmed SARS-CoV-2 
infection. In analyses of the primary outcomes restricted 
to this group, the estimated benefits of azithromycin 
remained below the predefined thresholds of clinically 
meaningful benefit. The low proportion of confirmed 
SARS-CoV-2 infections reflects the management of 
COVID-19 in UK primary care at the time of the study, 
when testing was not always available to many patients, 
and might reflect current practice in other community 
settings or low-income hospital settings, where access 
to timely SARS-CoV-2 diagnostic testing remains 
restricted and early empirical treatment might be used in 
symptomatic patients. This approach is supported by 
primary care data, which suggest that during the first 
wave of the pandemic in the UK, mor tality was similar 
among people with PCR-confirmed SARS-CoV-2 infec-
tion and people with COVID-19 diagnosed clinically 
by GPs.31
Our trial was open label, as the study question 
concerned whether the addition of azithromycin to 
usual care was effective, rather than a comparison 
between azithromycin and placebo. In the context of a 
rapidly adapting platform trial, it would be logistically 
difficult to produce a placebo for the multiple drug 
Azithromycin plus 
usual care (n=500)





Sustained recovery 317/500 (63%) 414/629 (66%) ·· ··
Time to sustained recovery 
(days)
19 (7 to not 
reached)
20 (7 to not 
reached) 
0·94 (0·81 to 1·09)* 0·39
Alleviation of all symptoms 401/420 (95%) 473/505 (94%) ·· ··
Time to alleviation of all 
symptoms (days)
3 (1 to 7) 3 (1 to 7) 1·04 (0·91 to 1·19)* 0·57
Sustained alleviation of all 
symptoms
338/422 (80%) 425/510 (83%) ·· ··
Time to sustained alleviation 
of all symptoms (days)
8 (3 to 27) 10 (3 to 24) 0·94 (0·81 to 1·09)* 0·40
Initial reduction of severity 
of symptoms
449/494 (91%) 554/622 (89%) ·· ··
Time to initial reduction of 
severity of symptoms (days)
4 (2 to 10) 4 (1 to 11) 0·99 (0·88 to 1·13)* 0·91
Rating of how well participant feels (1 worst, 10 best)
Day 7 7·2 (1·8) [484] 7·1 (1·9) [620] 0·10 (–0·12 to 0·32)† 0·36
Day 14 7·8 (1·8) [484] 7·7 (1·7) [613] 0·08 (–0·16 to 0·32)† 0·51
Day 21 8·0 (1·7) [421] 8·0 (1·6) [539] 0·03 (–0·25 to 0·30)† 0·86
Day 28 8·0 (1·7) [497] 8·3 (1·6) [612] –0·15 (–0·46 to 0·16)† 0·33
Wellbeing (WHO-5 Well-Being Index score)
Day 14 45·3 (23·8) [472] 44·1 (24·1) [601] 0·61 (–1·89 to 3·11)† 0·63
Day 28 52·9 (23·9) [474] 53·4 (24·3) [590] –0·06 (–2·56 to 2·44)† 0·96
Self-reported contact with 
one or more health-care 
services
255/499 (51%) 323/628 (51%) 1·00 (0·89 to 1·12)‡ 0·99
General practitioner 
reported contact with one or 
more health-care services
173/287 (60%) 200/387 (52%) 1·16 (1·01 to 1·32)‡ 0·039
Prescription of antibiotics 20/271 (7%) 26/353 (7%) 1·00 (0·57 to 1·76)§ >0·99
Hospital assessment without 
admission
9/500 (2%) 11/629 (2%) 1·03 (0·43 to 2·46)§ >0·99
Oxygen administration 10/497 (2%) 15/625 (2%) 0·84 (0·38 to 1·85)§ 0·69
Mechanical ventilation 2/496 (<1%) 5/625 (1%) 0·50 (0·10 to 2·59)§ 0·47
Intensive care unit 
admission
3/495 (1%) 5/625 (1%) 0·76 (0·18 to 3·15)§ >0·99
Data are n/N (%), median (IQR), or mean (SD) [n]. All secondary outcome analyses were analysed in the concurrent 
randomisation analysis population but restricted to those in the azithromycin plus usual care and usual care alone 
groups. HR=hazard ratio. *Estimated HR derived from a Cox proportional hazard model adjusted for age, comorbidities 
at baseline, duration of illness, and eligibility for azithromycin at baseline, with 95% CI. †Mixed effect model adjusted 
for age, comorbidity, duration of illness, eligibility for azithromycin at baseline, and time. Participant was fitted as a 
random effect; WHO-5 Well-Being Index score was also adjusted for the score at baseline. ‡Relative risk adjusted for 
age, comorbidities at baseline, duration of illness, and eligibility for azithromycin at baseline. §Unadjusted relative risk 
due to low event rate.
Table 3: Secondary outcomes
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treatments that are being added to PRINCIPLE as new 
evidence emerges. As participants were not masked to 
the intervention, self-reported outcomes might have 
been influenced by a placebo effect, although the effect 
of masking on estimates of effect has not been clearly 
shown.32 In our study, any potential placebo effect will 
have probably biased results towards a positive effect of 
azithromycin, meaning our finding of no effect on 
self-reported time to first recovery is robust to potential 
type II error. Our findings were similar for the hos-
pitalisation or death outcome, which is less susceptible 
to ascertainment bias.
In conclusion, our findings show that azithromycin 
should not be used routinely to treat COVID-19 in the 
community in older adults, in the absence of additional 
indications. These findings have important antibiotic 
stewardship implications during this pandemic, as 
inappropriate use of antibiotics leads to increased anti-
biotic resistance, and there is evidence that azithromycin 
use increased during the pandemic in the UK.7 Using 
antibiotics to treat COVID-19 might also encourage 
patients to believe that antibiotics are an appropriate 
treatment for other viral respiratory infections, and our 
findings guide clinicians to avoid prescribing antibiotics 
to patients seeking treatment for COVID-19 in the 
absence of an additional indication. Finally, our findings 
highlight the importance of randomised controlled 
trials to assess medications during the COVID-19 
pandemic and prevent the use of ineffective medications 
which, in the case of azithromycin, might contribute to 
other public health problems such as antimicrobial 
resistance.
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